Implantable Cardioverter Defibrillator Prevents Sudden Cardiac Death in Systemic Sclerosis

PASQUALE BERNARDO, MARIA LETIZIA CONFORTI, SILVIA BELLANDO-RANDONE, PAOLO PIERAGNOLI, JELENA BLAGOJEVIC, OLGA KALOUDI, SERENA GUIDUCCI, FRANCESCO PORTA, LUIGI PADELETTI, GIAN FRANCO GENISINI, and MARCO MATUCCI-CERINIC

ABSTRACT. Objective. Cardiac involvement means a poor prognosis in systemic sclerosis (SSc). Conduction defects and arrhythmias are frequent in patients with SSc, and may result in sudden cardiac death. We tested whether electrophysiologic studies and implantation of cardioverter defibrillators are recommended when ventricular arrhythmias are present.

Method. A cardioverter defibrillator was implanted in 10 patients with SSc who had heart involvement.

Result. After 36 months, analysis of the device showed several episodes of ventricular tachycardia in 3 patients, which were promptly reverted by electrical shock delivery.

Conclusion. In patients with SSc who are affected by ventricular arrhythmias, the implantation of a cardioverter defibrillator may prevent sudden cardiac death. (First Release June 1 2011; J Rheumatol 2011;38:1617–21; doi:10.3899/jrheum.100480)

Key Indexing Terms:

Sudden Cardiac Death
Implantable Cardioverter Defibrillator
Ventricular Tachyarrhythmias
Systemic Sclerosis

Systemic sclerosis (SSc) is a remarkably heterogeneous disease in which all organs may be involved to different degrees and progression of fibrosis. Heart involvement is sometimes unnoticed and is frequently detected at postmortem examination. Arrhythmias may be the first manifestation of heart involvement and are commonly detected during ambulatory monitoring. SSc carries the threat of sudden cardiac death (SCD), especially in diffuse cutaneous SSc (dcSSc), reported in 21% to 54% of patients with SSc. It is likely caused by malignant ventricular tachycardia (VT). Overall, heart involvement is more frequent and severe in dcSSc, even though it is also present in limited cutaneous SSc (lcSSc). However, in an epidemiologic study, no significant difference in the onset of heart symptoms was detected between dcSSc and lcSSc. Supraventricular and ventricular ectopy have been associated with increased mortality in SSc, independently from visceral involvement or disease severity. Moreover, VT occurs almost exclusively within the first few years of the onset of SSc. Clinical factors such as age and systemic extent of SSc correlate with cardiac rhythm disturbances observed by ambulatory electrocardiography (ECG). However, conflicting data have emerged on the predictive value of lung disease for ventricular tachyarrhythmias. The duration of the disease, the extent of skin involvement, and the presence of serum antitopoisomerase antibody did not predict ventricular arrhythmias.

There is no evidence that drug therapy may decrease SCD mortality in patients with SSc. In one SSc case, an implantable cardioverter defibrillator (ICD) prevented SCD. We report on a series of patients with SSc in whom the ICD has contributed to prevention of SCD.

MATERIALS AND METHODS

Ten patients with SSc were observed (6 women and 4 men, mean age 48.6 ± 15.4 yrs, mean disease duration 2.5 ± 4.6 yrs). They had ventricular arrhythmias on 24-h Holter monitoring and were referred to the Department of Rheumatology of the University of Florence from 2007 to 2009.

Patients were classified as lcSSc (1 patient) or dcSSc (9 patients) and assessed according to international consensus criteria. Antinuclear antibodies, antitopoisomerase I, and anticientromere antibodies were determined. Concomitant treatment included antiarrhythmic drugs (amiodarone, carvedilol, calcium-channel blockers), cyclophosphamide, and vasodilators. All patients underwent ECG, Holter ECG, Doppler echocardiography and tissue Doppler imaging, pulmonary function tests, lung high-resolution computed tomography (HRCT), measurement of plasma renin activity, and 24-h urine collection for protein excretion and creatinine clearance (Table 1).

All patients underwent myocardial scintigraphy and were examined by Tc-99 single-photon emission CT using a MillenniumTM gamma camera (GE Healthcare, Waukesha, WI, USA) at rest and after dipyridamole stress. In 4

From the Department of Critical Care Medicine and Surgery, and the Department of Biomedicine, Division of Rheumatology AOUC, Donothe Centre, University of Florence, Florence, Italy.

P. Bernardo, MD, Department of Critical Care Medicine and Surgery; M.L. Conforti, MD; S. Bellando-Randone, MD, Department of Biomedicine, Division of Rheumatology AOUC, Donothe Centre; P. Pieragnoli, MD, Department of Critical Care Medicine and Surgery; J. Blagojevic, MD; O. Kaloudi, MD; S. Guiducci, MD, PhD; F. Porta, MD, Department of Biomedicine, Division of Rheumatology AOUC, Donothe Centre; L. Padeletti, MD; G.F. Gensini, MD, Department of Critical Care Medicine and Surgery; M. Matucci-Cerinic, MD, PhD, Department of Biomedicine, Division of Rheumatology AOUC, Donothe Centre, University of Florence.

Address correspondence to Dr. M. Matucci-Cerinic, Department of Biomedicine, Division of Rheumatology AOUC, Villa Monna Tessa, V. le Pieraccini 18, 50139 Florence, Italy. E-mail: cerinic@unifi.it

Accepted for publication February 9, 2011.
patients with abnormal perfusion, coronarography was performed, and one
patient, with monocoronary disease, was treated with percutaneous translu-
reminal coronary angioplasty and stenting.

Patients’ informed consent was obtained before implantation. All patients
were implanted with a third-generation ICD device (Guidant Corp., Indianapolis,
IN, USA, and St. Jude Medical, model Epic DR, St. Paul, MN, USA) pro-
grammed to abort VT faster than 180 c/min. Before implantation of the ICD, 9
of the 10 patients were treated with antiarrhythmic drugs. In 2 patients, amio-
darone was stopped because of retinal deposition and thyroid dysfunction. No
patients were taking aspirin, and all were nonsmokers. Patients were followed up
at 3, 6, 12, 24, and 36 months through analysis of the ICD recorder.

The cases. Clinical features and laboratory data of the patients with SSc are
summarized in Table 2.

At ECG, defects of conduction were detected: 4 patients showed
first-degree atrioventricular block, 3 had left anterior fascicular block, and 4
showed right bundle-branch block. At Holter ECG, 3 patients presented >
5000 premature ventricular contractions (PVC), 4 patients > 1000 PVC, and
in 4 patients unsustained VT was registered. Moreover, in 2 patients a reduced
RR variability was found. The remaining patients showed a great number of
ventricular and supraventricular arrhythmias. Echocardiography revealed
minimal mitral regurgitation in 6 patients and 1 patient with mild mitral steno-
sis without regurgitation. Left ventricular dysfunction (ejection fraction 29%)

Table 1. Drug treatment and instrumental data of patients with systemic sclerosis (SSc).

<table>
<thead>
<tr>
<th>Patient</th>
<th>Treatment</th>
<th>sPAP, mm Hg</th>
<th>Creatinine Clearance, ml/min</th>
<th>FVC/DLCO, (%)</th>
<th>TDI/EA Ejection Fraction, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Amiodarone (withdrawn because of hypothyroidism)</td>
<td>30</td>
<td>138</td>
<td>77/35</td>
<td>0.6</td>
</tr>
<tr>
<td>2</td>
<td>Amiodarone (withdrawn because of retinal deposits), calcium-channel blockers</td>
<td>30</td>
<td>76.2</td>
<td>98/64</td>
<td>1.3</td>
</tr>
<tr>
<td>3</td>
<td>Amiodarone</td>
<td>50</td>
<td>80</td>
<td>38/35</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>Amiodarone, flecainide</td>
<td>25</td>
<td>87</td>
<td>110/130</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>Amiodarone</td>
<td>35</td>
<td>70</td>
<td>81/67</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>6</td>
<td>Carvedilol</td>
<td>30</td>
<td>48</td>
<td>124/59</td>
<td>Close to normal</td>
</tr>
<tr>
<td>7</td>
<td>No drug treatment</td>
<td>25</td>
<td>50.2</td>
<td>76/72</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>8</td>
<td>Amiodarone</td>
<td>20</td>
<td>82</td>
<td>88/68</td>
<td>&gt; 1</td>
</tr>
<tr>
<td>9</td>
<td>Amiodarone</td>
<td>35</td>
<td>60</td>
<td>86/38</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>10</td>
<td>Clopidogrel, diltiazem</td>
<td>30</td>
<td>85</td>
<td>60/29</td>
<td>&lt; 1</td>
</tr>
</tbody>
</table>

sPAP: systemic pulmonary arterial pressure; FVC: forced vital capacity; DLCO: diffusion lung capacity for carbon monoxide; TDI: tissue Doppler imaging; E/A ratio: (E) peak velocity of the early inflow phase, (A) peak velocity of the atrial inflow phase; NA: not applicable.

Table 2. Clinical and laboratory data of patients with systemic sclerosis (SSc).

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, yrs, Sex</th>
<th>SSc Form</th>
<th>Autoantibodies</th>
<th>ECG</th>
<th>ECG-Holter</th>
<th>Echocardiographic Abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32 M</td>
<td>dcSSc</td>
<td>Scl-70</td>
<td>RBBB</td>
<td>VT 28s CF 232 c/min</td>
<td>Mild left ventricular hypertrophy/mild MR</td>
</tr>
<tr>
<td>2</td>
<td>53 M</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>SR, LAFB</td>
<td>No. PVC: 7565 Pairs: 237 (13 runs of ventr. bigeminy)</td>
<td>Segmental hypokinesia of septum and apex; mild MR</td>
</tr>
<tr>
<td>3</td>
<td>56 M</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>SR, LAFB</td>
<td>No. PVC: 2958 Pairs: 48 18 runs of SVT R on T: 36 100 VT of 4 PVC</td>
<td>TDI negative, dilated left atrium (stenosis LAD 90% treated with PTCA)</td>
</tr>
<tr>
<td>4</td>
<td>32 F</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>SR, RBBB, first-degree AVB</td>
<td>No. PVC: 5000 Pairs: 114 VT: 2 episodes RR variability reduced</td>
<td>No abnormalities Mild MR</td>
</tr>
<tr>
<td>6</td>
<td>39 F</td>
<td>lcSSc</td>
<td>ANA</td>
<td>SR, first-degree AVB, RBBB, LAFB</td>
<td>No. PSVC: 2302 Pairs: 26 Triplets:1</td>
<td>Dilatative biventricular cardiomyopathy intraventricular asynchronism on TDI Mid pericardial effusion Diastolic dysfunction with restrictive pattern Mild pericardial effusion Diastolic dysfunction Mild mitral and tricuspid regurgitation Moderate severe aortic stenosis without regurgitation Diffuse hypokinesia stenosis LAD 30–40%</td>
</tr>
<tr>
<td>7</td>
<td>53 F</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>SR, first-degree AVB</td>
<td>No. PVC: 2302 Pairs: 26 Triples:1</td>
<td>Mild mitral and tricuspid regurgitation</td>
</tr>
<tr>
<td>8</td>
<td>29 F</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>SR</td>
<td>No. PSVC: 1069 Pairs: 13</td>
<td>Mild mitral and tricuspid regurgitation</td>
</tr>
<tr>
<td>9</td>
<td>57 F</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>Bradycardia Isolated ventr. extrasystole</td>
<td>No. PSVC: 1392 Pairs: 22</td>
<td>Moderate-severe aortic stenosis without regurgitation</td>
</tr>
<tr>
<td>10</td>
<td>30 M</td>
<td>dcSSc</td>
<td>ANA, Scl-70</td>
<td>Atrial tachycardia RBBB</td>
<td>No. PVC: 5526 Pairs: 34 Two episodes of ventricular tachycardias</td>
<td>Diffuse hypokinesia stenosis LAD 30–40%</td>
</tr>
</tbody>
</table>

ECG: echocardiogram; dcSSc: diffuse cutaneous SSc; ANA: antinuclear antibodies; CF: cardiac frequency; RBBB: right bundle-branch block; VT: ventricu-
lar tachycardia; MR: mitral regurgitation; SVT: supraventricular tachycardia; PVC: premature ventricular contractions; TDI: tissue Doppler imaging; PSVC: premature supraventricular contractions; LAFB: left anterior fascicular block; AVB: atrioventricular block; LAD: left anterior descending coronary artery; PTCA: percutaneous transluminal coronary angioplasty; SR: sinus rhythm.
was observed in 1 patient. Tissue Doppler imaging detected a diastolic dysfunction in 6 patients. In 7 patients, ICD analysis did not show any episodes of shocks and cardiac rhythm was normal during 36 months of followup. In 3 patients, during 36 months of followup, the ICD disclosed episodes of VT, promptly reverted by electrical shock.

**Patient 1.** A 32-year-old patient with dcSSc (first non-Raynaud’s symptom in 2000) had lung involvement [decreased DLCO (35%) and chest HRCT indicating interstitial lung disease] treated with monthly pulse cyclophosphamide (1 g/m²). Echocardiography was normal but Holter monitoring detected episodes of sustained VT. During one of these, the patient had a syncpe in spite of antiarrhythmic therapy with amiodarone. For this reason, an ICD was implanted (St. Jude Medical model Epic DR). In the followup, 2 significant episodes of malignant VT were detected, with a prompt shock discharge and recovery of the sinus rhythm. Moreover, rare episodes of supraventricular arrhythmia were registered. Therefore, therapy with mexiletine was started.

**Patient 2.** A 53-year-old patient with dcSSc (first non-Raynaud’s symptom in 1999) had esophageal and muscle involvement and exertion dyspnea. Pulmonary function tests, lung HRCT, and pulmonary artery pressure were normal. Doppler echocardiography showed left ventricular asynergy with normal ejection fraction. Cardiac scintigraphy revealed inducible ischemia of the apex and septum, but coronaryography did not demonstrate occlusions of the main coronary arteries. Cardiac Holter monitoring detected 7567 monomorphic PVC with 34 pairs and 13 runs of bigeminy. Amiodarone was withdrawn for hypothyroidism. An ICD (Guidant) was implanted. After 6 months of followup, the ICD showed 4 episodes of malignant VT that were interrupted with DC defibrillator current shock (Figure 1).

**Patient 3.** A 30-year-old patient with dcSSc (antinuclear antibody-positive, Scl-70-positive). Holter monitoring detected 5526 monomorphic PVC with 237 pairs and 13 runs of bigeminy. Amiodarone was withdrawn for hyperlipidemia. Coronary angiography showed a reduction of 30%–40% of the apex and septum, but coronaryography did not demonstrate occlusions of the main coronary arteries. Cardiac Holter monitoring detected 7567 monomorphic PVC with 34 pairs and 1 nonsustained VT. Echocardiography showed diffuse left ventricular hypokinesia and reduced ejection fraction (30%). The patient was not hyperlipidemic. Coronary angiography showed a reduction of 30%–40% of the left coronary artery. Therefore, an ICD was implanted (St. Jude Medical model). After 6 months, the ICD showed 5 malignant VT episodes interrupted with defibrillator current shock after inefficient acceleration time pulsation (Figures 2 and 3).

**DISCUSSION**

The mechanisms underlying ventricular arrhythmias in SSc are complex. Pathologic studies have shown diffuse myocardial fibrosis that provides a substrate for re-entry episodes, but automatic or triggered arrhythmias may also occur. In the literature, only 1 case of SSc with automatic tachycardia, treated with surgical ablation, has been reported. It has been suggested that monomorphic tachycardia in SSc can be sustained by a re-entry mechanism. In SSc, the arrhythmogenic substrate may result from dynamic vasospasm rather than reduced small coronary perfusion. Indeed, recurrent episodes of coronary spasm in SSc may be reactive to peripheral cold exposure and may be one of the causes of myocardial fibrosis. It could be that patients have both vasospasm and reduced small-vessel perfusion. Unfortunately, this issue remains unresolved. It has been shown that 21% of deaths in patients with SSc were due to SCD and that 12 out of 22 deaths in 183 patients with SSc were due to SCD. In 24% of patients at high risk with both cardiac and skeletal myopathy, sustained VT was documented and 48% died of SCD. In addition to spontaneous VT, the use of antiarrhythmic drugs was predictive of an adverse outcome in this SSc population. A number of diseases other than dilated cardiomyopathy have been associated with an increased incidence of SCD. These include inherited diseases of ion channels, such as long-QT syndrome (LQTS), Brugada syndrome, and catecholaminergic VT. Other structural heart diseases, such as right ventricular dysplasia, hypertrophic cardiomyopathy, and certain types of congenital heart disease, may also be associated with increased risk of SCD. The frequency of these conditions is not as high as that of ischemic or nonischemic dilated cardiomyopathy, so it is difficult to perform randomized controlled trials. Nonrandomized observational studies suggest that high-risk patients may benefit from ICD, and from this it may be inferred that patients with SSc who have VT might also benefit from ICD implantation. One case provides evidence of the clinical usefulness of ICD. In the absence of large-scale trials, there are some disease-specific markers, such as the length of the QT interval in the inherited LQTS, the presence of persistent rather than intermittent right precordial ST elevation in Brugada syndrome, and the degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. These conditions may indicate an increased risk of SCD and make ICD an appropriate choice to prevent it. In SSc, the presence of frequent premature ventricular contractions, such as recurrent couplets, or nonsustained VT, sustained VT with or without symptoms, may represent possible risk factors for SCD.

There is no evidence that drug therapy decreases mortality
in patients with SSc who have VT. The outcome of these patients may even be worse because of the proarrhythmic effect of the antiarrhythmic drug. In other diseases there is evidence that the ICD implant represents an effective therapy for life-threatening ventricular arrhythmias, and that treatment is considered appropriate for patients with complex ventricular arrhythmias. In addition to delivering shocks to stop malignant arrhythmias, the second-generation and third-generation ICD have a variety of pacing schemes to stop more stable VT.

Our data strongly suggest that ICD implantation should be considered in cases of SSc with malignant ventricular arrhythmias either unresponsive to or with contraindication to drug therapy. It remains to be determined whether patients with SSc who have reduced ejection fraction or dilated cardiomyopathy might also profit from the implantation of a pacemaker-defibrillator.

Figure 2. In the Holter echocardiogram, the onset of ventricular tachycardia is visible with inefficient overdrive.

Figure 3. Echocardiogram shows sustained ventricular tachycardia interrupted with DC shock.
REFERENCES


